Neurocrine Biosciences | NBIX - Selling And Administration Expenses


Neurocrine Biosciences reported $301.8M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Prothena USD 13.24M 2.67M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Repligen USD 73.66M 2.43M Sep/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xoma USD 11M 2.54M Jun/2024